Meet the Author Amin H. Nassar by Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer shared on X/Twitter:
“Meet the Author: Amin H. Nassar, a medical oncology fellow from Yale Cancer Center, is co-1st author of ‘Clinical Outcomes and Safety of Immune Checkpoint Inhibitors in Patients with Solid Tumors and Paraneoplastic Syndromes,’ recently published in JITC!
1/6
Dr. Nassar was inspired to become a researcher by the remarkable advancements made in cancer treatment. He is motivated to contribute knowledge that enables future breakthroughs and treatment innovations and he hopes to make a tangible difference for those living with cancer.
2/6
He is most excited about the possibility of reprogramming tumors to enhance immune recognition and killing. He is pursuing a career as a physician-scientist and hopes to find ways to genetically reprogram ‘cold’ tumors into ‘hot’ ones.
3/6
He will be graduating as a medical oncology fellow next year (clinical focus in thoracic oncology) and plans to apply for physician-scientist positions with a focus on tumor immunology.
4/6
He is proud to publish in JITC because ‘JITC provides state-of-the-art research in the field of immunology. The review process is rigorous and well-structured.’
5/6
Outside of research, Dr. Nassar loves soccer and board games! You can always count on him for a game of Catan.
Read his recent work here.
6/6″
Source: Journal for ImmunoTherapy of Cancer/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023